Zobrazeno 1 - 10
of 29 516
pro vyhledávání: '"Phases of clinical research"'
Autor:
Akiharu Kurihara, Takamaru Koda, Satoru Kagami, Kimihiko Yoshida, Atsuro Terahara, Kimihiko Funahashi, Tomoaki Kaneko, Mitsunori Ushigome, Yasuo Nagashima, Yasuyuki Miura
Publikováno v:
Reports of Practical Oncology and Radiotherapy. 28:36-46
Background: Preoperative chemoradiotherapy (CRT) for patients with rectal cancer has not yet been established in Japan. We conducted a non-randomized phase II study to evaluate the efficacy and safety of preoperative CRT with S-1, a fixed-dose combin
Publikováno v:
Hepatobiliary Surgery and Nutrition. 12:37-44
Autor:
Ken Kato, Akihiro Sato, Toshihiko Doi, Masashi Wakabayashi, Atsushi Ohtsu, Hiroki Hara, Shunji Takahashi, Takashi Kojima, Tomohiro Nishina, Shogo Nomura, Kei Muro
Publikováno v:
Esophagus. 19:702-710
4069 Background: BKM120 is an oral pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, which showed promising activity in breast cancer and squamous cell carcinoma of head and neck. We prospectively investigated clinical activity, safety and
Autor:
Hyun Ae Jung, Hye Ryeon Kim, Sehhoon Park, Se-Hoon Lee, Man Ki Chung, Myung-Ju Ahn, Han-Sin Jeong, Su Jin Lee
Publikováno v:
Cancer Research and Treatment. 54:719-727
Purpose Salivary gland cancers (SGCs) are relatively rare but comprise various histologic subtypes, which complicates design of prospective trials. Systemic chemotherapy plays a limited role in treatment of SGCs, but cisplatin and docetaxel showed ef
Publikováno v:
Cancer/Radiothérapie. 26:604-610
Because of the physical properties of proton beam radiation therapy (PT), which allows energy to be deposited at a specific depth with a rapid energy fall-off beyond that depth, PT has several theoretical advantages over photon radiation therapy for
Autor:
Hidetoshi Hayashi, Mototsugu Shimokawa, Naoki Haratake, Tomohiro Sakamoto, Kazuhiko Nakagawa, Masahide Oki, Hiroshige Yoshioka, Yusuke Nakano, Nobuyuki Yamamoto, Koichi Azuma, Takashi Seto, Keiichi Ota
Publikováno v:
Clinical Lung Cancer. 23:e257-e263
Introduction : Osimertinib is a standard first-line treatment for non–small cell lung cancer (NSCLC) harboring mutations of the epidermal growth factor receptor gene (EGFR). However, tumors with the L858R mutation appear to be less sensitive to EGF
Autor:
Deanna Kornacki, Moshe Talpaz, Josef T. Prchal, Jason Clark, Srdan Verstovsek, Solomon I. Hamburg, Philomena Colucci, Murat O. Arcasoy, Lawrence B. Afrin
Publikováno v:
Clinical lymphoma, myeloma & leukemia, vol 22, iss 5
Introduction : Treatment options in patients with myelofibrosis (MF) presenting with thrombocytopenia are limited. Final results of the phase 2 study (NCT01348490) of ruxolitinib in patients with MF and low baseline platelet counts (50–100 × 109/L
Publikováno v:
Clinical Gastroenterology and Hepatology. 20:e1192-e1195
Biologic treatment options for Crohn's disease (CD) are increasing and providers will need enhanced support in integrating these therapies into routine practice. Using phase 3 clinical trial programs in CD, we have previously built and validated clin
Autor:
Tiantian Zheng, Pan Du, Caitlin Bennett, Jianjun Yu, Heidi Fettke, Carmel Pezaro, Lavinia Spain, Chao Dai, Gargi Kothari, Shidong Jia, Linda Garrett, Ben Tran, Deborah Chang, M. Shaw, Elizabeth Liow, Angelyn Anton, Arun Azad, Chun L. Gan, Edmond M. Kwan, Shankar Siva, Claire Abou-Seif, Phillip Parente
Publikováno v:
European Urology. 81:253-262
Background Immune checkpoint inhibitor monotherapy in metastatic castration-resistant prostate cancer (mCRPC) has produced modest results. High-dose radiotherapy may be synergistic with checkpoint inhibitors. Objective To evaluate the efficacy and sa
Autor:
Bryan C. Cannon, M. Yasir Qureshi, Kimberly A. Holst, Philip L. Wackel, Dawit T. Haile, Joan Wobig, Joseph A. Dearani, Shakila P. Khan, Karen Cavanaugh, Timothy M. Olson, Drew K. Seisler, Patrick W. O'Leary, Timothy J. Nelson
Publikováno v:
The Annals of Thoracic Surgery. 113:890-895
Background The objective of this study is to assess the safety and early impact of intramyocardial delivery of autologous bone marrow–derived mononuclear cells (BM-MNC) at time of surgical Ebstein repair. Methods Patients with Ebstein anomaly (ages